Wall Street brokerages expect Icon Plc (NASDAQ:ICLR) to post $676.54 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Icon’s earnings, with the lowest sales estimate coming in at $669.50 million and the highest estimate coming in at $693.25 million. Icon reported sales of $455.14 million during the same quarter last year, which indicates a positive year over year growth rate of 48.6%. The firm is expected to report its next earnings results on Thursday, February 21st.

According to Zacks, analysts expect that Icon will report full year sales of $2.59 billion for the current fiscal year, with estimates ranging from $2.59 billion to $2.61 billion. For the next year, analysts expect that the company will post sales of $2.79 billion, with estimates ranging from $2.77 billion to $2.83 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Icon.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 24th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.54. Icon had a net margin of 12.88% and a return on equity of 26.08%. The company had revenue of $655.02 million during the quarter, compared to analyst estimates of $654.66 million.

ICLR has been the subject of several recent research reports. BidaskClub lowered shares of Icon from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 21st. Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $163.00 target price for the company in a research note on Thursday, August 9th. Robert W. Baird restated a “buy” rating and issued a $154.00 target price on shares of Icon in a research note on Thursday, July 26th. SunTrust Banks upped their target price on shares of Icon to $153.00 and gave the company a “buy” rating in a research note on Thursday, July 26th. Finally, Mizuho set a $146.00 target price on shares of Icon and gave the company a “hold” rating in a research note on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $148.00.

Hedge funds and other institutional investors have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale boosted its stake in Icon by 119.7% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 419 shares during the last quarter. Fort L.P. bought a new position in Icon during the 2nd quarter valued at $121,000. Capital Advisors Ltd. LLC bought a new position in Icon during the 3rd quarter valued at $121,000. Csenge Advisory Group bought a new position in Icon during the 3rd quarter valued at $150,000. Finally, Prudential Financial Inc. bought a new position in shares of Icon in the 3rd quarter worth about $200,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Shares of Icon stock traded up $1.39 during trading hours on Friday, hitting $129.34. The company’s stock had a trading volume of 22,177 shares, compared to its average volume of 250,160. Icon has a 1-year low of $101.22 and a 1-year high of $155.33. The firm has a market capitalization of $7.19 billion, a P/E ratio of 23.83, a PEG ratio of 1.91 and a beta of 0.50. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.26.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading: Swap

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.